Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VNRX Stock Forecast 2025-2026
$0.50
Current Price
$50.39M
Market Cap
Buy 4
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to VNRX Price Targets
+904.0%
To High Target of $5.00
+402.0%
To Median Target of $2.50
+301.6%
To Low Target of $2.00
VNRX Price Momentum
0.0%
1 Week Change
+2.0%
1 Month Change
-39.8%
1 Year Change
-16.7%
Year-to-Date Change
-44.7%
From 52W High of $0.90
+18.6%
From 52W Low of $0.42
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching VolitionRX (VNRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on VNRX and similar high-potential opportunities.
Latest VNRX Stock Price Targets & Analyst Predictions
Based on our analysis of 11 Wall Street analysts, VNRX has a bullish consensus with a median price target of $2.50 (ranging from $2.00 to $5.00). The overall analyst rating is Strong Buy (8.4/10). Currently trading at $0.50, the median forecast implies a 402.0% upside. This outlook is supported by 4 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 904.0% upside. Conversely, the most conservative target is provided by Kyle Mikson at Cantor Fitzgerald, suggesting a 301.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VNRX Analyst Ratings
4
Buy
1
Hold
0
Sell
VNRX Price Target Range
Low
$2.00
Average
$2.50
High
$5.00
Current: $0.50
Latest VNRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VNRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Apr 11, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $2.50 |
| Apr 8, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $2.50 |
| Apr 1, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 31, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 20, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 13, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Mar 4, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Feb 6, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Jan 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Jan 8, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Dec 10, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Nov 22, 2024 | Benchmark | Bruce Jackson | Hold | Reiterates | $0.00 |
| Nov 15, 2024 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $5.00 |
| Nov 1, 2024 | EF Hutton | Jason Kolbert | Buy | Maintains | $5.00 |
| Aug 26, 2024 | EF Hutton | Tim Moore | Buy | Assumes | $5.00 |
| Aug 16, 2024 | Benchmark | Bruce Jackson | Hold | Reiterates | $0.00 |
| Jun 7, 2024 | EF Hutton | Tim Moore | Buy | Maintains | $4.00 |
| May 16, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $2.50 |
VolitionRx Limited (VNRX) Competitors
The following stocks are similar to VolitionRX based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
VolitionRx Limited (VNRX) Financial Data
VolitionRx Limited has a market capitalization of $50.39M with a P/E ratio of 0.0x. The company generates $1.23M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -21.4% quarter-over-quarter, while maintaining an operating margin of -3,016.5% and return on equity of +103.3%.
Valuation Metrics
Market Cap
$50.39M
Enterprise Value
$51.32M
P/E Ratio
0.0x
PEG Ratio
-3.1x
Price/Sales
40.8x
Growth & Margins
Revenue Growth (YoY)
-21.4%
Gross Margin
N/A
Operating Margin
-3,016.5%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+6.8%
Current Ratio
0.5x
Debt/Equity
-0.2x
ROE
+103.3%
ROA
-90.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
VolitionRx Limited (VNRX) Business Model
About VolitionRx Limited
What They Do
Develops blood tests for cancer detection.
Business Model
VolitionRx Limited generates revenue by developing and commercializing blood tests that utilize its Nu.Q platform to detect various cancers and diseases. The company collaborates with healthcare institutions to validate its diagnostic tools, aiming to provide non-invasive and cost-effective solutions that enhance early detection and patient outcomes.
Additional Information
Headquartered in Austin, Texas, with operations in Belgium, VolitionRx is positioned in the growing fields of precision medicine and early diagnosis. The company's innovative approach to health diagnostics places it at the forefront of medical technology, with the potential to significantly impact healthcare and improve survival rates through timely intervention.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
85
CEO
Mr. Cameron Reynolds MBA
Country
United States
IPO Year
2012
Website
www.volition.comVolitionRx Limited (VNRX) Latest News & Analysis
Latest News
Quick Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) provided a commercial update on its Nu.Q® NETs product, announced by Chief Commercial Officer Gael Forterre, on May 7, 2025.
Why It Matters
The update on Nu.Q® NETs indicates potential revenue growth and market positioning for VolitionRx, influencing stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (NYSE: VNRX) announced a business update from President and CEO Cameron Reynolds in a Shareholder Letter on April 29, 2025.
Why It Matters
VolitionRx's shareholder update may signal strategic developments or financial performance insights, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited will hold its Q4 2024 earnings conference call on March 31, 2025, at 4:30 PM ET, featuring key executives and industry analysts.
Why It Matters
VolitionRx's Q4 2024 earnings call signals upcoming financial performance insights, potentially impacting stock valuation and investor sentiment. Key executives' insights can influence market reactions.
Source: Seeking Alpha
Market Sentiment:
Neutral
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update
1 month ago
Quick Summary
VolitionRx Limited (NYSE: VNRX) will host a conference call on March 31, 2025, at 4:30 p.m. ET to discuss its Q4 and full-year financial results for 2024.
Why It Matters
The upcoming conference call will provide critical insights into VolitionRx's financial performance and strategic direction, impacting investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a virtual investor event on April 9, 2025, at 10:00 AM ET, featuring key executives from the company.
Why It Matters
VolitionRx's virtual investor event may reveal strategic updates and insights from key executives, impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025
1 month ago
Quick Summary
VolitionRx presented studies at ELCC 2025 showing that its Nu.Q®H3K27Me3 biomarker and ctDNA can enhance prognostic value in NSCLC and its Nu.Q® H3.1 can identify high cancer risk individuals.
Why It Matters
VolitionRx's advancements in cancer biomarkers may enhance treatment strategies and early detection, potentially increasing market demand and boosting investor confidence in the company's future growth.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About VNRX Stock
What is VolitionRx Limited's (VNRX) stock forecast for 2025?
Based on our analysis of 11 Wall Street analysts, VolitionRx Limited (VNRX) has a median price target of $2.50. The highest price target is $5.00 and the lowest is $2.00.
Is VNRX stock a good investment in 2025?
According to current analyst ratings, VNRX has 4 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VNRX stock?
Wall Street analysts predict VNRX stock could reach $2.50 in the next 12 months. This represents a 402.0% increase from the current price of $0.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is VolitionRx Limited's business model?
VolitionRx Limited generates revenue by developing and commercializing blood tests that utilize its Nu.Q platform to detect various cancers and diseases. The company collaborates with healthcare institutions to validate its diagnostic tools, aiming to provide non-invasive and cost-effective solutions that enhance early detection and patient outcomes.
What is the highest forecasted price for VNRX VolitionRx Limited?
The highest price target for VNRX is $5.00 from Jason Kolbert at D. Boral Capital, which represents a 904.0% increase from the current price of $0.50.
What is the lowest forecasted price for VNRX VolitionRx Limited?
The lowest price target for VNRX is $2.00 from Kyle Mikson at Cantor Fitzgerald, which represents a 301.6% increase from the current price of $0.50.
What is the overall VNRX consensus from analysts for VolitionRx Limited?
The overall analyst consensus for VNRX is bullish. Out of 11 Wall Street analysts, 4 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $2.50.
How accurate are VNRX stock price projections?
Stock price projections, including those for VolitionRx Limited, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 12:00 AM UTC